Cancer Medicine最新文献

{"title":"Correction to “Global Trend in Pancreatic Cancer Prevalence Rates Through 2040: An Illness-Death Modeling Study”","authors":"","doi":"10.1002/cam4.70417","DOIUrl":"10.1002/cam4.70417","url":null,"abstract":"<p>Hesami Z, Olfatifar M, Sadeghi A, Zali MR, Mohammadi-Yeganeh S, Habibi MA, Ghadir MR, Houri H. Global Trend in Pancreatic Cancer Prevalence Rates Through 2040: An Illness-Death Modeling Study. <i>Cancer Med</i>. 2024 Oct;13(20):e70318. https://doi.org/10.1002/cam4.70318</p><p>The Ethical Code Acknowledgment is missing in the published paper. The Ethics Statement, “This project has been ethically approved by the Ethics Committee at Qom University of Medical Sciences, Qom, Iran (No. IR.MUQ.REC.1402.186).” should be placed after the Acknowledgment section.</p><p>We apologize for this error.</p>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"13 22","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70417","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142646103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Machine Learning Models to Predict Bone Metastasis Risk in Patients With Lung Cancer","authors":"Kevin Wang Leong So,&nbsp;Evan Mang Ching Leung,&nbsp;Tommy Ng,&nbsp;Rachel Tsui,&nbsp;Jason Pui Yin Cheung,&nbsp;Siu-Wai Choi","doi":"10.1002/cam4.70383","DOIUrl":"https://doi.org/10.1002/cam4.70383","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>The aim of this study was to find the most appropriate variables to input into machine learning algorithms to identify those patients with primary lung malignancy with high risk for metastasis to the bone.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Patient Inclusion</h3>\u0000 \u0000 <p>Patients with either histological or radiological diagnoses of lung cancer were included in this study.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The patient cohort comprised 1864 patients diagnosed from 2016 to 2021. A total of 25 variables were considered as potential risk factors. These variables have been identified in previous studies as independent risk factors for bone metastasis. Treatment methods for lung cancer were taken into account during model development. The outcome variable was binary, (presence or absence of bone metastasis) with follow-up until death or 12-month survival, whichever is the sooner. Results showed that American Joint Committee on Cancer staging, the use of EGFR inhibitor, age, T-staging, and lymphovascular invasion were the five input features contributing the most to the model algorithm. High AJCC staging (OR 1.98; <i>p</i> &lt; 0.05), the use of EGFR inhibitor (OR 6.14; <i>p</i> &lt; 0.05), high T-staging (OR 1.47; <i>p</i> &lt; 0.05), and the presence of lymphovascular invasion (OR 4.92; <i>p</i> &lt; 0.05) increase predicted risk of bone metastasis. Conversely, older age reduces predicted bone metastasis risk (OR 0.98; <i>p</i> &lt; 0.05).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The machine learning model developed in this study can be easily incorporated into the hospital's Clinical Management System so that input variables can be immediately utilized to give an accurate prediction of bone metastatic risk, therefore informing clinicians on the best treatment strategy for that individual patient.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"13 22","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70383","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142666129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nurse-Led Screening-Triggered Early Specialized Palliative Care Program for Patients With Advanced Lung Cancer: A Multicenter Randomized Controlled Trial","authors":"Yoshihisa Matsumoto,&nbsp;Shigeki Umemura,&nbsp;Ayumi Okizaki,&nbsp;Daisuke Fujisawa,&nbsp;Takuhiro Yamaguchi,&nbsp;Shunsuke Oyamada,&nbsp;Tempei Miyaji,&nbsp;Tomoe Mashiko,&nbsp;Naoko Kobayashi,&nbsp;Eriko Satomi,&nbsp;Daisuke Kiuchi,&nbsp;Tatsuya Morita,&nbsp;Yosuke Uchitomi,&nbsp;Koichi Goto,&nbsp;Yuichiro Ohe","doi":"10.1002/cam4.70325","DOIUrl":"https://doi.org/10.1002/cam4.70325","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>We aimed to examine the effectiveness of a nurse-led, screening-triggered early specialized palliative care intervention program for patients with advanced lung cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients with advanced lung cancer who underwent initial chemotherapy were randomized to intervention and usual care groups between January 2017 and September 2019. The intervention comprised comprehensive needs assessments, counseling, and service coordination by advanced-level nurses. Patients in the usual care group received the usual oncological care. The primary end point was a change in the trial outcome index (TOI) scores from baseline to 12 weeks. The secondary end-points were TOI scores at week 20, depression, anxiety, and survival.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In total, 102 patients were assigned to each group. Compared with the usual care group, no significant improvement in TOI scores was observed at 12 weeks in the intervention group (mean group difference: 2.13; 90% confidence interval: −0.70, 4.95; <i>p</i> = 0.107, one-sided), whereas significant improvement was observed at 20 weeks (3.58; 90% confidence interval: 0.15, 7.00; <i>p</i> = 0.043). There were no significant differences in the change from baseline depression and anxiety between the groups from baseline at week 12 and 20 weeks (depression: <i>p</i> = 0.60 and 0.10, anxiety: <i>p</i> = 0.78 and 0.067). Survival did not significantly differ between the groups (median survival time: 12.1 vs. 11.1 months; <i>p</i> = 0.302).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Nurse-led, screening-triggered, early specialized palliative care did not show significant superiority over usual care during the 12-week study period. However, it may have yielded delayed clinical benefits, such as improved quality of life and this feasible model can be acceptable in clinical practice.</p>\u0000 \u0000 <p><b>Trial Registration:</b> The University Hospital Medical Information Network Clinical Trials Registry: UMIN000025491</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"13 22","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70325","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142666039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Outcomes of Neoadjuvant Therapy Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma","authors":"Kyung In Shin,&nbsp;Min Sung Yoon,&nbsp;Jee Hoon Kim,&nbsp;Won Joon Jang,&nbsp;Galam Leem,&nbsp;Jung Hyun Jo,&nbsp;Moon Jae Chung,&nbsp;Jeong Youp Park,&nbsp;Seung Woo Park,&nbsp;Ho Kyoung Hwang,&nbsp;Chang Moo Kang,&nbsp;Seung-seob Kim,&nbsp;Mi-Suk Park,&nbsp;Hee Seung Lee,&nbsp;Seungmin Bang","doi":"10.1002/cam4.70363","DOIUrl":"10.1002/cam4.70363","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>This study aimed to compare the long-term effects of neoadjuvant therapy and upfront surgery on overall survival (OS) and progression-free survival (PFS) in patients with resectable pancreatic ductal adenocarcinoma (PDAC).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrospectively analyzed 202 patients, including 167 who had upfront surgery and 35 who received neoadjuvant therapy followed by surgery. Surgical outcomes and survival rates were compared using propensity score matching to minimize selection bias.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Neoadjuvant therapy showed significantly longer 75% OS (72.7 months vs. 28.3 months, <i>p</i> = 0.032) and PFS (29.6 months vs. 13.2 months, <i>p</i> &lt; 0.001) compared to upfront surgery. Additionally, neoadjuvant therapy demonstrated significant improvements in surgical outcomes, including higher R0 resection rates (74.3% vs. 49.5%, <i>p</i> = 0.034), reduced tumor size (22.0 mm vs. 28.0 mm, <i>p</i> = 0.001), and decreased lymphovascular invasion (20.0% vs. 52.4%, <i>p</i> = 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our study demonstrates the potential benefits of neoadjuvant therapy for resectable PDAC. The improved survival rates, delayed disease progression, and enhanced surgical outcomes underscore the potential of neoadjuvant therapy in addressing this aggressive disease. Despite limitations such as the retrospective design and small sample size, these findings support the effectiveness of neoadjuvant therapy in improving treatment outcomes for PDAC patients in real-world settings. Further prospective studies are required to validate these results.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"13 22","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70363","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142646111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Calcium Channel Blocker Versus Renin–Angiotensin System Inhibitor in Risk of Kidney Cancer Among Patients With Hypertension: A Propensity Score-Matched Cohort Study","authors":"Minji Jung,&nbsp;Shufeng Li,&nbsp;Zhengyi Deng,&nbsp;Jinhui Li,&nbsp;Mingyi Li,&nbsp;Satvir Basran,&nbsp;Marvin E. Langston,&nbsp;Benjamin I. Chung","doi":"10.1002/cam4.70429","DOIUrl":"10.1002/cam4.70429","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Use of antihypertensive medications could be associated with an increased risk of kidney cancer. Despite their various mechanisms of action, whether this association differs between different classes of medications remains unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The objective of this study is to compare the risk of kidney cancer between first-line treatment options of antihypertensive medications in a hypertensive population.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>In this retrospective cohort study, we used the MarketScan Databases (2007–2021). We included individuals older than 30 years of age with a diagnosis of hypertension who received first-line medications for hypertension, which included three classes: angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), and dihydropyridine calcium channel blockers (dCCB). We applied a propensity score matching method and created three separate cohorts: (1) ARB versus ACEI, (2) dCCB versus ACEI, and (3) dCCB versus ACEI. For non-dCCB, we repeated the analyses. The primary outcome was kidney cancer incidence. To assess kidney cancer risk, we applied multivariable conditional Cox proportional hazards models.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In the first cohort, ARB use was associated with an increased risk of kidney cancer compared to ACEI use (hazard ratio [HR] 1.10, 95% confidence interval [CI] 1.02–1.18). In the second cohort, dCCB use was associated with an increased risk of kidney cancer compared to ACEI use (HR 1.29, 95% CI 1.18–1.40). In the third cohort, dCCB use was associated with a higher risk of kidney cancer compared to ARB use (HR 1.17, 95% CI 1.08–1.28). Null association was shown when comparing non-dCCB with ACEI or ARB use.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Use of dCCB showed a higher risk of kidney cancer compared to ACEI or ARB use in patients with hypertension.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"13 22","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11568363/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142643525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Capturing Chemotherapy and Radiotherapy Dose Among Breast Cancer Patients With the Utah All-Payer Claims Database Compared With Gold-Standard Abstraction","authors":"Alzina Koric,&nbsp;Chun-Pin Esther Chang,&nbsp;Shane Lloyd,&nbsp;Mark Dodson,&nbsp;Vikrant G. Deshmukh,&nbsp;Michael G. Newman,&nbsp;Ankita P. Date,&nbsp;Jen A. Doherty,&nbsp;Lisa H. Gren,&nbsp;Christina A. Porucznik,&nbsp;Benjamin A. Haaland,&nbsp;N. Lynn Henry,&nbsp;Mia Hashibe","doi":"10.1002/cam4.70411","DOIUrl":"10.1002/cam4.70411","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To evaluate the validity of the Utah statewide All-Payer Claims Database (APCD), we compared breast cancer-specific treatments and dosages with gold-standard abstraction of medical records.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Study Design</h3>\u0000 \u0000 <p>In this pilot study, breast cancer treatments were abstracted by a certified tumor registrar at the Utah Cancer Registry (UCR) for patients diagnosed in 2013 with breast cancer. The abstraction of medical records was the <i>gold standard</i> for comparison with treatments identified in the APCD. The reliability and agreement between the treatment identified in the APCD and abstraction data were measured with sensitivity and specificity. Dose consistency was measured with the intraclass correlation coefficients (ICC).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Compared with the 186 abstractions, the sensitivity of the APCD to identify chemotherapy agents was high: 89% for any agent, 91% for carboplatin, 83% for docetaxel, 82% for doxorubicin, or 94.7% for biologic therapy. The consistency between the chemotherapy dosage identified in the claims and the abstraction varied from 63% to 76%. For radiotherapy, the sensitivity of the claims to identify the completed radiotherapy regimen was 66%. The ICC between radiotherapy doses identified in the claims and the abstraction was 54% (95% confidence interval [CI], 48%, 67%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Employing these novel methods, the claims were highly reliable in identifying cancer treatment agents overall, namely carboplatin, docetaxel, and trastuzumab. The claims were of moderate utility in capturing the treatment dose information. In addition to the APCD, the use of multiple data sources improved the completeness of cancer treatment information.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"13 22","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11568241/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142643526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gliosarcoma: A Multi-Institutional Analysis on Clinical Outcomes and Prognostic Factors","authors":"Siyer Roohani,&nbsp;Maximilian Mirwald,&nbsp;Felix Ehret,&nbsp;Christoph Fink,&nbsp;Laila König,&nbsp;Jana Käthe Striefler,&nbsp;Noelle Samira Jacob,&nbsp;Ilinca Popp,&nbsp;Johannes Steffel,&nbsp;Jolina Handtke,&nbsp;Noa Marie Claßen,&nbsp;Titus Rotermund,&nbsp;Daniel Zips,&nbsp;Peter Vajkoczy,&nbsp;Ulrich Schüller,&nbsp;Mateusz Jacek Spałek,&nbsp;David Kaul","doi":"10.1002/cam4.70347","DOIUrl":"10.1002/cam4.70347","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose</h3>\u0000 \u0000 <p>This study describes oncological outcomes and investigates prognostic factors for patients with gliosarcomas (GSM).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Histopathologically confirmed GSM patients who underwent treatment at five European institutions were retrospectively analyzed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We analyzed 170 patients with a median clinical follow-up time of 9.2 months. The majority received surgery (94.1%), postoperative radiotherapy (pRT, 81.8%), and temozolomide (TMZ)-based postoperative chemotherapy (66.5%). The median overall survival (OS) and progression-free survival (PFS) were 12.3 and 6.6 months, respectively. In the multivariable Cox regression analysis (MVA), the following factors were significantly associated with OS: age per year (hazard ratio (HR): 1.03, <i>p</i> &lt; 0.001), subtotal resection (STR) versus biopsy only (HR: 0.15, <i>p</i> = 0.018), gross total resection (GTR) versus biopsy only (HR: 0.13, <i>p</i> = 0.011), pRT versus no pRT (HR: 0.20, <i>p</i> &lt; 0.001), postoperative TMZ-based chemotherapy versus no postoperative chemotherapy (HR: 0.44, <i>p</i> = 0.003), <i>MGMT</i> promoter non-methylated versus methylated (HR: 1.79, <i>p</i> = 0.05), and tumor diameter per cm (HR: 1.15, <i>p</i> = 0.046). For PFS, the following factors were significantly associated in the MVA: GTR versus biopsy only (HR: 0.19, <i>p</i> = 0.026), pRT versus no pRT (HR: 0.36, <i>p</i> = 0.006), postoperative TMZ-based chemotherapy vs. no postoperative chemotherapy (HR: 0.39, <i>p</i> &lt; 0.001), <i>MGMT</i> promoter status unknown versus methylated (HR: 1.69, <i>p</i> = 0.034), and tumor diameter per cm (HR: 1.18, <i>p</i> = 0.016). Sex, primary or secondary GSM, and <i>TP53</i> mutational status were not significantly associated with OS or PFS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Trimodal therapy comprising surgical resection, pRT and TMZ-based chemotherapy appears to have the most beneficial effect on survival in GSM patients. Smaller tumor size, younger age and methylated <i>MGMT</i> promoters are associated with improved survival. To our knowledge, this is the largest multi-institutional cohort study investigating outcomes and prognostic factors for GSM.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"13 22","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70347","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142637955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RETRACTION: Pard3 Suppresses Glioma Invasion by Regulating RhoA Through Atypical Protein Kinase C/NF-κB Signaling","authors":"","doi":"10.1002/cam4.70408","DOIUrl":"10.1002/cam4.70408","url":null,"abstract":"<p><b>RETRACTION:</b> J. Li, H. Xu, Q. Wang, P. Fu, T. Huang, O. Anas, H. Zhao and N. Xiong, “Pard3 Suppresses Glioma Invasion by Regulating RhoA Through Atypical Protein Kinase C/NF-κB Signaling,” <i>Cancer Medicine</i> 8, no. 5 (2019): 2288–2302, https://doi.org/10.1002/cam4.2063.</p><p>The above article, published online on 07 March 2019 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor-in-Chief, Stephen Tait; and John Wiley &amp; Sons Ltd. The retraction has been agreed due to several instances of image overlaps observed in Figures 7C, 2F, 2G, 4F, 4G, 2D, 3D, 4D, 2E, 3E and 4E. Furthermore, elements from Figures 2F, 2G and 4G were found published in an article elsewhere in the same year by a different author group. Additionally, elements from Figures 2E and 3E were also published in another article in the same year by some of the same authors. The authors responded to the concerns and provided some data. However, their explanation and data provided were insufficient. Due to the nature and extent of the duplications, the editors consider the results and conclusion of this article to be invalid. The authors disagree with the retraction.</p>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"13 22","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70408","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142637956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establishment and Validation of a Prognostic Nomogram for Predicting Postoperative Overall Survival in Advanced Stage III–IV Colorectal Cancer Patients","authors":"Pengwei Lou,&nbsp;Dongmei Luo,&nbsp;Yuting Huang,&nbsp;Chen Chen,&nbsp;Shuai Yuan,&nbsp;Kai Wang","doi":"10.1002/cam4.70385","DOIUrl":"10.1002/cam4.70385","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Most colorectal cancer (CRC) patients are at an advanced stage when they are first diagnosed. Risk factors for predicting overall survival (OS) in advanced stage CRC patients are crucial, and constructing a prognostic nomogram model is a scientific method for survival analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 2956 advanced stage CRC patients were randomised into training and validation groups at a 7:3 ratio. Univariate and multivariate Cox proportional hazards regression analyses were used to screen risk factors for OS and subsequently construct a prognostic nomogram model for predicting 1-, 3-, 5-, 8- and 10-year OS of advanced stage CRC patients. The performance of the model was demonstrated by the area under the curve (AUC) values, calibration curves and decision curve analysis (DCA). Kaplan–Meier curves were used to plot the survival probabilities for different strata of each risk factor.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>There was no statistically significant difference (<i>p</i> &gt; 0.05) in the 32 clinical variables between patients in the training and validation groups. Univariate and multivariate Cox proportional hazards regression analyses demonstrated that age, location, TNM, chemotherapy, liver metastasis, lung metastasis, MSH6, CEA, CA199, CA125 and CA724 were risk factors for OS. We estimated the AUC values for the nomogram model to predict 1-, 3-, 5-, 8- and 10-year OS, which in the training group were 0.826 (95% CI: 0.807–0.845), 0.836 (0.819–0.853), 0.839 (0.820–0.859), 0.835 (0.809–0.862) and 0.825 (0.779–0.870) respectively; in the validation group, the corresponding AUC values were 0.819 (0.786–0.852), 0.831 (0.804–0.858), 0.830 (0.799–0.861), 0.815 (0.774–0.857) and 0.802 (0.723–0.882) respectively. Finally, the 1-, 3-, 5-, 8- and 10-year OS rates for advanced stage CRC patients were 73.4 (71.8–75.0), 49.5 (47.8–51.4), 43.3 (41.5–45.2), 40.1 (38.1–41.9) and 38.6 (36.6–40.8) respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>We constructed and validated an original nomogram for predicting the postoperative OS of advanced stage CRC patients, which can help facilitates physicians to accurately assess the individual survival of postoperative patients and identify high-risk patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"13 22","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70385","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142637954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Novel Prognostic Nomogram Based on TIGIT and NKG2A Can Predict Relapse-Free Survival of Hepatocellular Carcinoma After Hepatectomy","authors":"Junqi Wang,&nbsp;Yuqing Cao,&nbsp;Yu Tian,&nbsp;Chaoliu Dai,&nbsp;Tianqiang Jin,&nbsp;Feng Xu","doi":"10.1002/cam4.70419","DOIUrl":"10.1002/cam4.70419","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Objectives</h3>\u0000 \u0000 <p>Hepatocellular carcinoma (HCC) is a major global health concern, and emerging evidence suggests that TIGIT and NKG2A are potential immune checkpoints with implications for HCC progression. This study aimed to evaluate the prognostic significance of TIGIT and NKG2A expression in HCC patients who underwent radical liver resection.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a retrospective analysis of 144 HCC patients who underwent radical liver resection. TIGIT and NKG2A expression levels were assessed using the immunoreactive score. Cox proportional hazards models were utilized to analyze the association between TIGIT/NKG2A expression and clinical characteristics, relapse-free survival (RFS), and overall survival (OS). Prognostic models for OS and RFS was developed and validated using concordance index and calibration curves. Additionally, the random forest algorithm was employed to identify independent risk factors for OS and RFS and their correlation with predicted survival.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>TIGIT and NKG2A expression were identified as independent risk factors for RFS, while TIGIT expression alone significantly impacted OS. The prognostic models showed good discriminative ability, with concordance indices exceeding 0.7 for predicting 1-, 3-, and 5-year OS or RFS. Calibration curves confirmed the reliability of the nomograms for OS and RFS prediction. The areas under the ROC curve consistently exceeded 0.7 for predicting OS and RFS. Elevated levels of TIGIT and NKG2A expression were associated with diminished RFS, highlighting their importance as prognostic factors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our study establishes the prognostic significance of TIGIT and NKG2A expression in predicting OS and RFS following radical liver resection for HCC patients. The developed prognostic models incorporating TIGIT and NKG2A expression hold promise for improving risk stratification and clinical management of HCC patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"13 22","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11561519/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}